Background: Thrombus embolization and microvascular obstruction during percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) is commonly detected, which causes inadequate myocardial perfusion and elevated infarct size. An approach with low-dose intracoronary fibrinolytic treatment for reducing distal embolization and improving myocardial reperfusion in high-risk STEMI cases remains controversial. Methods: The RECOVER II study represents a multicenter, randomized, double-blind, parallel-group trial assessing low-dose adjunctive intracoronary reteplase during primary PCI in individuals with large anterior myocardial infarction and thrombus determined by angiography. The trial will enroll 306 cases who present within 12 h following STEMI for proximal or mid left anterior descending artery occlusion undergoing primary PCI. Cases will be randomized to receive a bolus intracoronary reteplase at 9 mg or 18 mg vs. placebo. The drug will be delivered over 2 minutes proximal to culprit lesions with an intracoronary catheter early after wire-crossing and before thrombus aspiration or balloon dilation. Results: The primary outcome will be infarct size assessed by late gadolinium-enhanced magnetic resonance imaging (MRI) (% of left ventricular mass) on day 7 after enrollment. Secondary outcomes will include the amount of microvascular obstruction and myocardial salvage index examined via MRI on day 7, angiographic measures of reperfusion [Thrombolysis in Myocardial Infarction (TIMI) coronary flow grade, TIMI frames count and myocardial blush grade], incidence of complete ST-segment resolution at 2 hours after reperfusion, area under the curve for troponin T, and rates of major adverse cardiovascular events at 30 days. Conclusions: RECOVER II will determine whether the addition of low-dose intracoronary reteplase early after wire-crossing as an adjunct to reperfusion treatment reduces infarct size in individuals with large anterior myocardial infarction. Trial Registration: ClinicalTrials.gov Identifier: NCT04571580. 2022 Cardiovascular Diagnosis and Therapy. All rights reserved.
Background: Thrombus embolization and microvascular obstruction during percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) is commonly detected, which causes inadequate myocardial perfusion and elevated infarct size. An approach with low-dose intracoronary fibrinolytic treatment for reducing distal embolization and improving myocardial reperfusion in high-risk STEMI cases remains controversial. Methods: The RECOVER II study represents a multicenter, randomized, double-blind, parallel-group trial assessing low-dose adjunctive intracoronary reteplase during primary PCI in individuals with large anterior myocardial infarction and thrombus determined by angiography. The trial will enroll 306 cases who present within 12 h following STEMI for proximal or mid left anterior descending artery occlusion undergoing primary PCI. Cases will be randomized to receive a bolus intracoronary reteplase at 9 mg or 18 mg vs. placebo. The drug will be delivered over 2 minutes proximal to culprit lesions with an intracoronary catheter early after wire-crossing and before thrombus aspiration or balloon dilation. Results: The primary outcome will be infarct size assessed by late gadolinium-enhanced magnetic resonance imaging (MRI) (% of left ventricular mass) on day 7 after enrollment. Secondary outcomes will include the amount of microvascular obstruction and myocardial salvage index examined via MRI on day 7, angiographic measures of reperfusion [Thrombolysis in Myocardial Infarction (TIMI) coronary flow grade, TIMI frames count and myocardial blush grade], incidence of complete ST-segment resolution at 2 hours after reperfusion, area under the curve for troponin T, and rates of major adverse cardiovascular events at 30 days. Conclusions: RECOVER II will determine whether the addition of low-dose intracoronary reteplase early after wire-crossing as an adjunct to reperfusion treatment reduces infarct size in individuals with large anterior myocardial infarction. Trial Registration: ClinicalTrials.gov Identifier: NCT04571580. 2022 Cardiovascular Diagnosis and Therapy. All rights reserved.
Authors: Peter J McCartney; Hany Eteiba; Annette M Maznyczka; Margaret McEntegart; John P Greenwood; Douglas F Muir; Saqib Chowdhary; Anthony H Gershlick; Clare Appleby; James M Cotton; Andrew Wragg; Nick Curzen; Keith G Oldroyd; Mitchell Lindsay; J Paul Rocchiccioli; Aadil Shaukat; Richard Good; Stuart Watkins; Keith Robertson; Christopher Malkin; Lynn Martin; Lynsey Gillespie; Thomas J Ford; Mark C Petrie; Peter W Macfarlane; R Campbell Tait; Paul Welsh; Naveed Sattar; Robin A Weir; Keith A Fox; Ian Ford; Alex McConnachie; Colin Berry Journal: JAMA Date: 2019-01-01 Impact factor: 56.272
Authors: Stephen G Ellis; Michal Tendera; Mark A de Belder; Ad J van Boven; Petr Widimsky; Luc Janssens; H R Andersen; Amadeo Betriu; Stefano Savonitto; Jerzy Adamus; Jan Z Peruga; Maciej Kosmider; Olivier Katz; Thomas Neunteufl; Julia Jorgova; Maria Dorobantu; Liliana Grinfeld; Paul Armstrong; Bruce R Brodie; Howard C Herrmann; Gilles Montalescot; Franz-Josef Neumann; Mark B Effron; Elliot S Barnathan; Eric J Topol Journal: N Engl J Med Date: 2008-05-22 Impact factor: 91.245
Authors: Gregg W Stone; Harry P Selker; Holger Thiele; Manesh R Patel; James E Udelson; E Magnus Ohman; Akiko Maehara; Ingo Eitel; Christopher B Granger; Paul L Jenkins; Melissa Nichols; Ori Ben-Yehuda Journal: J Am Coll Cardiol Date: 2016-04-12 Impact factor: 24.094
Authors: Heerajnarain Bulluck; Nicolas Foin; Jack W Tan; Adrian F Low; Murat Sezer; Derek J Hausenloy Journal: Circ Cardiovasc Interv Date: 2017-03 Impact factor: 6.546
Authors: C M Gibson; J A de Lemos; S A Murphy; S J Marble; C H McCabe; C P Cannon; E M Antman; E Braunwald Journal: Circulation Date: 2001-05-29 Impact factor: 29.690
Authors: R Erbel; T Pop; K J Henrichs; K von Olshausen; C J Schuster; H J Rupprecht; C Steuernagel; J Meyer Journal: J Am Coll Cardiol Date: 1986-09 Impact factor: 24.094